InvestorsHub Logo
Followers 43
Posts 9124
Boards Moderated 0
Alias Born 01/06/2011

Re: biotechtrader2020 post# 226016

Thursday, 11/14/2019 3:18:01 PM

Thursday, November 14, 2019 3:18:01 PM

Post# of 427141
I think J.L. can word primary prevention class better than me. Primary prevention trails are tough, it's about screening people from the population that are at risk for a heart attack. I believe the Jupiter Trail did well because they went after a population with high inflammation, as we should do in the future. Perhaps screening patients for multiple inflammatory markers.

There is no doubt, that this drug would have a positive effect on primary prevention. It's up to the FDA to sort through the data and make a sound scientific decision.

P.S. Why we are excited to see the result of EVAPORATE trial later this week to be made public at the AHA meeting.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News